Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 6, Issue 1, 2014, Pages

  Elli, Elena Maria ^a   Belotti, Angelo ^a   Aroldi, Andrea ^a   Parma, Matteo ^a   Pioltelli, Pietro ^a   Pogliani, Enrico Maria ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; FERRITIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; AGE; AGED; ARTICLE; BLEEDING; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HEPATITIS; HUMAN; INCIDENCE; IRON CHELATION; IRON OVERLOAD; IRON THERAPY; KIDNEY FAILURE; MALABSORPTION; MALE; MUCOSAL DISEASE; MYELOID METAPLASIA; RASH; SEPSIS; SURVIVAL; ULCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CHELATION THERAPY; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG MEGADOSE; HEMOGLOBIN BLOOD LEVEL; HYPERTRANSAMINASEMIA; LEUKOCYTE COUNT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VERY ELDERLY;

EID: 84902602920     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2014.042     Document Type: Article

References (35)

1. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013;88 (2):141-50. PMID: 23349007 http://dx.doi.org/10.1002/ajh.23384
2. Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013;121 (24):4832-7. PMID: 23570800 http://dx.doi.org/10.1182/blood-2013-02-482232
3. Mesa RA, Barosi G, Cervantes F, Reilly JT, Tefferi A. Myelofibrosis with myeloid metaplasia: disease overview and nontransplant treatment options. Best Pract Res Clin Haematol. 2006;19 (3):495-517. PMID: 16781486 http://dx.doi.org/10.1016/j.beha.2005.07.008
4. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program. 2006;29-35. PMID: 17124036
5. Cohen AR. New advances in iron chelation therapy. Hematology Am Soc Hematol Educ Program. 2006;42-47. PMID: 17124038
6. Breuer W, Shvartsman M, Cabantchik ZI. Intracellular labile iron. Int J Biochem Cell Biol. 2008;40 (3):350-354. http://dx.doi.org/10.1016/j.biocel.2007.03.010 PMID: 1745199
7. Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int J Hematol. 2002;76 (3):219-228. PMID: 12416732
8. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115 (2):239-252. PMID: 11703317 http://dx.doi.org/10.1046/j.1365-2141.2001.03195.x
9. Tefferi A, Siragusa S, Hussein K, Schwager SM, Hanson CA, Pardanani A, Cervantes F, Passamonti F. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2010;85 (1):14-7. PMID: 2002995 http://dx.doi.org/10.1002/ajh.21574
10. Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT, Ibatici A, Raiola AM, Frassoni F, De Stefano F, Verdiani S, Casarino L, Barosi G. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant. 2010;45 (3):458-63. PMID: 19718055 http://dx.doi.org/10.1038/bmt.2009.188
11. Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol. 2007;79 (6):463-467. PMID: 17976187 http://dx.doi.org/10.1111/j.1600-0609.2007.00972.x
12. Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus. 2012;10:411-22. doi: http://dx.doi.org/10.2450/2012.0008-12 PMID: 22790257
13. Bennet JM. Consensus statement on iron overload in Myelodysplastic Syndromes. Am J Hematol. 2008;83:858-61. PMID: 18767130 http://dx.doi.org/10.1002/ajh.21269
14. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120 (18):3657-69. PMID: 22919029 http://dx.doi.org/10.1182/blood-2012-05-370098
15. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, El-Ali A, Habr D, Martin N, Porter JB. Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. Haematologica. 2013;98 (7):1045-8. PMID: 23585526 http://dx.doi.org/10.3324/haematol.2012.077669
16. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91 (12):1588-1590. PMID:17145593 PMid:17145593
17. Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96 (10):1433-40. PMID: 21659359 http://dx.doi.org/10.3324/haematol.2011.044602
18. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118(4): 884-93 PMID:21628399 http://dx.doi.org/10.1182/blood-2010-11-316646
19. Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, VassilieffD, Habr D, Domokos G, Roubert B, Rose C; EPIC study investigators. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res. 2010;34 (9):1143-50. PMID: 20451251 http://dx.doi.org/10.1016/j.leukres.2010.03.009
20. Leitch HA, Leger CS, Goodman TA, Wong KK, Wong DH, Ramadan KM, Rollins MD, Barnett MJ, Galbraith PF, Vickars LM. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clinical Leuk. 2008;2 (3):205-211. dx.doi.org/10.3816/CLK.2008.n.026
21. Chaudhary P, Pullarkat V. Deferasirox: appraisal of safety and efficacy in long-term therapy. J Blood Med. 2013;4:101-10. PMID: 23966805 http://dx.doi.org/10.2147/JBM.S35478
22. Breccia M, Alimena G. Efficacy and safety of deferasirox in myelodysplastic syndromes. Ann Hematol. 2013;92 (7):863-70. PMID: 23417759 http://dx.doi.org/10.1007/s00277-013-1703-7
23. Molica M, Salaroli A, Alimena G, Breccia M. Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome. Blood Transfus. 2014 Jan;12 Suppl 1: s162-3. http://dx.doi.org/10.2450/2013.0005-13 PMID: 23736908
24. Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, Schmid M, Taylor K, VassilieffD, Habr D, Marcellari A, Roubert B, Rose C. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97 (9):1364-71. PMID: 22419577 http://dx.doi.org/10.3324/haematol.2011.048546
25. Messa E, Carturan S, Maffè C, Pautasso M, Bracco E, Roetto A, Messa F, Arruga F, Defilippi I, Rosso V, Zanone C, Rotolo A, Greco E, Pellegrino RM, Alberti D, Saglio G, Cilloni D. Deferasirox is a powerful NF-kappa B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95 (8):1308-16. PMID: 18827475 http://dx.doi.org/10.3324/haematol.2009.016824
26. Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol. 2010;28 (1):40-8. PMID: 19557769 http://dx.doi.org/10.1002/hon.902
27. Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol. 2007;78 (6):540-2. PMID: 17391307 http://dx.doi.org/10.1111/j.1600-0609.2007.00840.x
28. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120 (2):70-4. PMID:18827475 http://dx.doi.org/10.1159/000158631
29. Tesch H, Ihling C. Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis - a case report. Onkologie. 2013;36 (4):205-8. PMID: 23548970 http://dx.doi.org/10.1159/000349939
30. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008;111 (2):583-7. PMID:17951527 http://dx.doi.org/10.1182/blood-2007-08-109306
31. Cheson BD1, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108 (2):419-25. PMID: 16609072 http://dx.doi.org/10.1182/blood-2005-10-4149
32. Del Corso L, Balleari E, Arboscello E, Ghio R, Mencoboni M, Racchi O. Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis. Case Rep Hematol. 2013; 2013:520712. PMID: 24307957 http://dx.doi.org/10.1155/2013/520712
33. Komura E, Tonetti C, Penard-Lacronique V, Chagraoui H, Lacout C, Lecouédic JP, Rameau P, Debili N, Vainchenker W, Giraudier S. Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res. 2005;65 (8):3281-9. http://dx.doi.org/10.1158/0008-5472 PMID: 15833861
34. Wagner-Ballon O, Pisani DF, Gastinne T, Tulliez M, Chaligné R, Lacout C, Auradé F, Villeval JL, Gonin P, Vainchenker W, Giraudier S. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood. 2007;110 (1):345-53. PMID:17374740 http://dx.doi.org/10.1182/blood-2006-10-054502
35. Barosi G, Gattoni E, Guglielmelli P, Campanelli R, Facchetti F, Fisogni S, Goldberg J, Marchioli R, Hoffman R, Vannucchi AM; Myeloproliferative Research Consortium. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. Am J Hematol. 2010;85 (8):616-9. PMID: 20540156 http://dx.doi.org/10.1002/ajh.21754